Other MPO inhibitors (e.g., AZD3241, AZD4831, SNT-8370, UFM24) have been investigated for their anti-inflammatory effects in neutrophilic lung injury, but their roles in lung cancer treatment warrant further exploration [145–147]. This evidence concerns the gene MPO and lung carcinoma.